European Commission approves Cyramza (ramucirumab)for indications in NSCLC and colorectal cancer-Eli Lilly
Eli Lilly and Company announced that the European Commission has approved Cyramza (ramucirumab) for two new indications : 1. in combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non small lung cancer (NSCLC) with disease progression after platinum based chemotherapy and 2. in combination with FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) for treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with Avastin (bevacizumab), oxiplatin and a fluoropyrimidine.
Comment: With this approval ramucirumab is the first EU medicine approved for use in combination with docetaxel in pre-treated patients with NSCLC regardless of histology.
Comment:Clinical data from the REVEL trial showed that the drug, given alongside docetaxel, helped extend survival by an average of 1.4 months in around half of the NSCLC patients treated with the combination, compared to half of those docetaxel plus a placebo. This trial included squamous (73%) and non squamous (23%) forms of NSCLC.
Comment: Colorectal cancer patients treated with the Cyramza plus FOLFIRI regimen in the RAISE trial achieved a median overall survival of 13.3 months versus those given placebo plus FOLFIRI who achieved 11.7 months, which has reduced the risk of patient death by 15%.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins